Unique ID issued by UMIN | UMIN000052433 |
---|---|
Receipt number | R000058733 |
Scientific Title | A Multicenter Prospective Cohort Study to Establish a Predictive Model for the Treatment-Related Acute Kidney Disease by Noninvasive Tubular Aging Assessment |
Date of disclosure of the study information | 2023/10/06 |
Last modified on | 2023/10/06 11:21:08 |
A Multicenter Prospective Cohort Study to Establish a Predictive Model for the Treatment-Related Acute Kidney Disease by Noninvasive Tubular Aging Assessment
A Multicenter Prospective Cohort Study to Establish a Predictive Model for the Treatment-Related Acute Kidney Disease by Noninvasive Tubular Aging Assessment
A Multicenter Prospective Cohort Study to Establish a Predictive Model for the Treatment-Related Acute Kidney Disease by Noninvasive Tubular Aging Assessment
A Multicenter Prospective Cohort Study to Establish a Predictive Model for the Treatment-Related Acute Kidney Disease by Noninvasive Tubular Aging Assessment
Japan |
acute kidney disease
Hematology and clinical oncology | Nephrology | Oto-rhino-laryngology |
Urology |
Malignancy
NO
The purpose of this study was to longitudinally evaluate the association between the degree of tubular senescence diagnosed by blood and urine cytology and the incidence of treatment-related acute kidney disease (AKD) in patients undergoing anti-tumor chemotherapy for malignancy at our hospital.
Safety
Onset of treatment-related AKD (failure of renal function recovery on day 7 or 30 after initiation of treatment: > 0.3 mg/dl or 1.5-fold increase in serum Cr compared to baseline)
1) Serum biomarker (soluble serum alpha Klotho)
2) Number of cells positive for P16 and P53 antibodies in urine cytology
3) Renal death and induction of dialysis (temporary or permanent)
4) Onset of AKI (>0.3 mg/dl increase in Cr value or >1.5-fold increase in Cr value or oliguria compared to baseline value within 2 days of starting treatment) and its stage
5) Development of CKD (decrease to eGFR <60 ml/min/1.73 m2 or positive urine protein: >1+ over 3 months of treatment)
6) Survival and treatment success rate (whether the planned treatment could be continued or not)
7) Age, gender, original disease, comorbidity (hypertension, diabetes, liver disease), concomitant medications, blood pressure, BMI
8) Details of treatment (dose and frequency of anti-tumor therapy, renal ischemia time, contrast medium dose, and volume of replacement fluid)
Observational
16 | years-old | <= |
Not applicable |
Male and Female
Patients undergoing anti-tumor chemotherapy
Under 16 years old
400
1st name | Tadashi |
Middle name | |
Last name | Sofue |
Kagawa University Hospital
Department of Nephrology
761-0793
1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa, Japan
087-891-2150
sofue.tadashi@kagawa-u.ac.jp
1st name | Tadashi |
Middle name | |
Last name | Sofue |
Kagawa University Hospital
Department of Nephrology
7610793
1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa, Japan
087-891-2150
sofue.tadashi@kagawa-u.ac.jp
Kagawa University
Kagawa University
Self funding
Kagawa University
1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa, Japan
0878912150
chiken-b.@med.kagawa-u.ac.jp
NO
2023 | Year | 10 | Month | 06 | Day |
Unpublished
Preinitiation
2023 | Year | 08 | Month | 25 | Day |
2023 | Year | 09 | Month | 25 | Day |
2023 | Year | 10 | Month | 01 | Day |
2028 | Year | 12 | Month | 31 | Day |
Observation study
2023 | Year | 10 | Month | 06 | Day |
2023 | Year | 10 | Month | 06 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000058733
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |